External Committees

Advisory Board

The ICER Advisory Board is comprised of Flagship members of ICER’s Policy Leadership Forum and other select stakeholders. The Advisory Board meets annually with ICER’s Governance Board to provide guidance on ICER’s overall portfolio of activities and strategic plan. The Advisory Board provides perspective and advice to ICER on how it can best fulfill its mission, but the Advisory Board has no direct governance role.

    • Lora Armstrong, PharmD, Vice President, Medical Affairs, CVS Health
    • Carmella Bocchino, RN, MBA , President and CEO, CRB Strategies, LLC
    • Anne B. Docimo, MD, MBA, Chief Medical Officer, UnitedHealthcare Clinical Services
    • Patrick Gleason, PharmD, Assistant Vice President, Health Outcomes, Prime Therapeutics
    • Tony Grillo, PharmD, Vice President, Financial Analysis and Forecasting, Express Scripts
    • Beth Hamilton, MBA, Vice President, Global Oncology Market Access & Pricing (OMAP), AstraZeneca
    • Ross Hoffman, MD, Chief Medical Officer, Envolve Pharmacy Solutions
    • Kyle Hvidsten, Head, Specialty Care Health Economics & Value Assessment, Sanofi
    • Myoung Kim, PhD, MBA, Vice President and Head, US Heath Economics and Outcomes Research and Medical Access, Novartis
    • Andreas Kuznik, PhD, Executive Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals, Inc.
    • Mark McClellan, MD, PhD, Founding Director, Duke-Margolis Center for Health Policy, Duke University
    • Megan McIntyre, PharmD, Vice President, Pharmacy and Clinical Consulting, Premera Blue Cross
    • Lilian Ndehi-Rice, PharmD, MBA, Associate Vice President, Clinical and Specialty Strategies, Humana
    • Robert Nordyke, PhD, Vice President, Research, National Pharmaceutical Council
    • Yeesha Poon, PhD, MBA, Director, Global Market Access & Health Economics, Abbott
    • Sulabha Ramachandran, PhD, Vice President, US and Regions, Value Evidence and Outcomes, GlaxoSmithKline
    • Gail Ryan, PharmD, Director of Pharmaceutical Transformation, Point32Health
    • David R. Strutton, PhD, Vice President, Global Pharmaceuticals and Policy Evidence Research, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc.
    • Sean D. Sullivan, PhD, Professor and Dean, University of Washington School of Pharmacy
    • Heidi C. Waters, PhD, MBA, Senior Director, Policy Research, Global Value & Real World Evidence, Otsuka Pharmaceutical

    Methods Advisory Group

    ICER’s Methods Advisory Group (MAG) meets three times per year to provide guidance on ICER’s methods for health technology assessments and other evaluations. In the past few years, the MAG has helped to shape a data in-confidence policy, develop a pilot for a model transparency program, and comment on the process and methods for ICER’s report evaluating price increases for high impact drugs.

      • Abbott
      • Anthem
      • AstraZeneca
      • CVS Caremark
      • Envolve Pharmacy Solutions
      • Express Scripts
      • GlaxoSmithKline
      • Humana
      • Kaiser Permanente
      • Merck & Co.
      • National Pharmaceutical Council
      • Novartis
      • Otsuka Pharmaceutical
      • Point32Health
      • Premera Blue Cross
      • Prime Therapeutics
      • Regeneron Pharmaceuticals, Inc.
      • Sanofi
      • UnitedHealthcare